Evidence map›Paper›PMID 30872685›Full record

ArticleScientific reports2019

An Effective Neutralizing Antibody Against Influenza Virus H1N1 from Human B Cells.

Cheng-Chung Lee, Chih-Ya Yang, Li-Ling Lin, Tzu-Ping Ko, Alarng Hsun-Lang Chang, Stanley Shi-Chung Chang, Andrew H-J Wang

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.8field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 21 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Neutralization of the Pandemic Influenza A/H1N1 Virus withAntibodies (Basel, Switzerland) · 2025
    Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Cheng-Chung LeeInstitute of Biological Chemistry, Academia Sinica, Taipei, Taiwan.
Chih-Ya YangDepartment of Science and Innovation, Medigen Biotech Corporation, Taipei, Taiwan.
Li-Ling LinInstitute of Biological Chemistry, Academia Sinica, Taipei, Taiwan.
Tzu-Ping KoInstitute of Biological Chemistry, Academia Sinica, Taipei, Taiwan.
Alarng Hsun-Lang ChangDepartment of Science and Innovation, Medigen Biotech Corporation, Taipei, Taiwan.
Stanley Shi-Chung ChangDepartment of Science and Innovation, Medigen Biotech Corporation, Taipei, Taiwan. sscchang@medigen.com.tw.
Andrew H-J WangInstitute of Biological Chemistry, Academia Sinica, Taipei, Taiwan. ahjwang@gate.sinica.edu.tw.
Academia Sinica · TWInstitute of Biological Chemistry, Academia Sinica · TW

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Influenza is a contagious acute respiratory disease caused by the influenza virus infection. Hemagglutinin (HA) is an important target in the therapeutic treatment and diagnostic detection of the influenza virus. Influenza A virus encompasses several different HA subtypes with different strains, which are constantly changing. In this study, we identified a fully human H1N1 neutralizing antibody (32D6) via an Epstein-Barr virus-immortalized B cell-based technology. 32D6 specifically neutralizes the clinically isolated H1N1 strains after the 2009 pandemic but not the earlier strains. The epitope was identified through X-ray crystallographic analysis of the 32D6-Fab/HA1 complex structure, which revealed a unique loop conformation located on the top surface of HA. The major region is composed of two peptide segments (residues 172-177 and 206-213), which form an abreast loop conformation. The residue T262 between the two loops forms a conformational epitope for recognition by 32D6. Three water molecules were observed at the interface of HA and the heavy chain, and they may constitute a stabilizing element for the 32D6-HA association. In addition, each 32D6-Fab is likely capable of blocking one HA trimer. This study provides important information on the strain specificity of 32D6 for the therapeutic treatment and detection of viral infection.

Indexed as

Antibodies, NeutralizingAntibodies, ViralB-LymphocytesCrystallography, X-RayEpitopesHemagglutinin Glycoproteins, Influenza VirusHumansInfluenza A Virus, H1N1 SubtypeInfluenza, HumanNeutralization TestsProtein ConformationAntibodies, NeutralizingAntibodies, ViralEpitopesHemagglutinin Glycoproteins, Influenza Virus

Identifiers

PMID30872685
PMCPMC6418199
OpenAlexW2921625605

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.